Risk factors for acute graft-versus-host disease

Authors

  • Robert Peter Gale,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    Search for more papers by this author
  • Mortimer M. Bortin,

    Corresponding author
    1. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, U.S.A
      Dr M. M. Bortin, International Bone Marrow Transplant Registry, Medical College of Wisconsin, P.O. Box 26509, Milwaukee, WI 53226, U.S.A.
    Search for more papers by this author
  • Dirk W. van Bekkum,

    1. Division of Health Research TNO, Radiobiological Institute, Rijswijk, The Netherlands
    Search for more papers by this author
  • James C. Biggs,

    1. Division of Hematology/Oncology, St Vincent's Hospital, Sydney, Australia
    Search for more papers by this author
  • Karel A. Dicke,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Department of Hematology, M.D. Anderson Hospital and Tumor Institute, Houston, TX, U.S.A
    Search for more papers by this author
  • Eliane Gluckman,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Service d'Hématologie, Hôpital Saint-Louis, Paris, France
    Search for more papers by this author
  • Robert A. Good,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Department of Pediatrics, All Children's Hospital, St Petersburg, FL, U.S. A
    Search for more papers by this author
  • Raymond G. Hoffmann,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Division of Biostatistics/Clinical Epidemiology, Medical College of Wisconsin, Milwaukee, WI, U.S. A
    Search for more papers by this author
  • Humphrey E. M. Kay,

    1. Department of Clinical Pathology, Royal Marsden Hospital, London, U.K.
    Search for more papers by this author
  • John H. Kersey,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
    Search for more papers by this author
  • Alberto Marmont,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Divisione di Ematologia, Ospedale San Martino, Genoa, Italy
    Search for more papers by this author
  • Tohru Masaoka,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Department of International Medicine, Center for Adult Diseases, Osaka, Japan
    Search for more papers by this author
  • Alfred A. Rimm,

    1. International Bone Marrow Transplant Registry and the Division of Hematology/Oncology, UCLA Center for the Health Sciences, Los Angeles, CA, U.S. A
    2. Division of Biostatistics/Clinical Epidemiology, Medical College of Wisconsin, Milwaukee, WI, U.S. A
    Search for more papers by this author
  • Jon J. van Rood,

    1. Department of Immunohaematology, University Hospital, Leiden, The Netherlands
    Search for more papers by this author
  • Ferdinand E. Zwaan

    1. Department of Medicine, University Hospital, Leiden, The Netherlands
    Search for more papers by this author

Dr M. M. Bortin, International Bone Marrow Transplant Registry, Medical College of Wisconsin, P.O. Box 26509, Milwaukee, WI 53226, U.S.A.

Abstract

Summary. Acute graft-versus-host disease (GvHD) is an important complication of bone marrow transplantation in humans. Risk factors are imprecisely defined and controversial. We analysed data from 2036 recipients of HLA-identical sibling transplants for leukaemia or aplastic anaemia to identify risk factors for GvHD. Analyses indicate that grading of GvHD can be reproducibly divided into absent or mild versus moderate to severe; 2-year actuarial probability was 54% (95% confidence interval 52–56%) for absent or mild and 46% (44–48%) for moderate to severe. Factors predictive of development of moderate to severe GvHD include donor/recipient sex-match (female→male greater than others, relative risk 2.0, P<0.001). This risk was markedly increased if female donors for male recipients were previously pregnant or transfused (relative risk 2.9, P<0.0001). Older patients were at increased risk of GvHD (relative risk 1.6, P<0.001), but the age gradient was modest, even the youngest patients had a substantial risk of GvHD and, if parous or transfused female→male transplants were excluded, age was not a significant risk factor. Cyclosporine or methotrexate were equally effective at preventing GvHD and were superior to no prophylaxis (relative risk 2.3, P<0.01). These data should be useful in estimating the risk of acute GvHD in an individual patient and in designing clinical trials to investigate methods to modify or prevent GvHD.

Ancillary